Biomarkers for the treatment of interstitial lung disease
AssigneeLung Therapeutics, Inc.
InventorsBreAnne MACKENZIE, Cory HOGABOAM
Life of this patent
Estimating the term…
Abstract
The present disclosure provides biomarkers associated with caveolin-1 peptide therapy in subjects with interstitial lung disease. In particular, the present disclosure describes biomarkers such as MYDGF, soluble RAGE, pSMAD2/3, and PDGFRβ associated with caveolin-1 peptide therapy in subjects with idiopathic pulmonary fibrosis. These biomarkers could be used to determine efficacy, monitoring, and optimal dosing of caveolin-1 peptide therapy in subjects with interstitial lung disease.
Claims144
A method for treating a subject with caveolin-1 peptide therapy, wherein the subject is suffering from fibrosis, the method comprising the steps of:
- (a) obtaining or having obtained a biological sample from the subject;
- (b) treating or having treated a cell of the biological sample with a caveolin-1 peptide or derivative thereof;
- (c) measuring an expression level of a biomarker in the cell;
- and
- (d) comparing the expression level of the biomarker to a control sample;
- wherein the biomarker is myeloid-derived growth factor (MYDGF), soluble RAGE, phosphorylated mothers against decapentaplegic homolog 2/3 (pSMAD2/3), platelet-derived growth factor receptor beta (PDGFRβ), galectin-7 (LGALS7), interleukin-11 (IL-11), matrix metalloproteinase-2 (MMP-2), chemokine ligand 7 (CXCL-7), soluble CD163, phosphorylated mTOR (p-mTOR), phosphorylated PDGFRβ (pPDGFRβ), prolifin (PROF1), calmodulin 2 (CALM2), calreticulin (CALR), peptidyl-prolyl cis-trans isomerase A (PPIA), or eukaryotic translation initiation factor 5A (EIF5A1);
- and
- if the expression level of MYDGF, PROF1, CALM2, CALR, PPIA, IF5A1, LGALS7, soluble RAGE, or EIF5A1 is increased, then administering caveolin-1 peptide or derivative thereof to the subject;
- or
- if the expression level of PDGFRβ, pPDGFRβ, p-mTOR, CALR, IL-11, MMP-2, CXCL7, soluble CD163, or pSMAD2/3 is decreased, then administering caveolin-1 peptide or derivative thereof to the subject.
A method of identifying an altered expression level of a biomarker associated with caveolin-1 peptide therapy, the method comprising:
- (a) treating a cell of a subject with interstitial lung disease with a caveolin-1 peptide or derivative thereof;
- (b) measuring an expression level of a biomarker in the cell;
- and
- (c) comparing the expression level of the biomarker to a control sample;
- wherein the caveolin-1 peptide or derivative thereof modulates the expression level of the biomarker in the cell;
- and
- wherein the biomarker is myeloid-derived growth factor (MYDGF), soluble RAGE, phosphorylated mothers against decapentaplegic homolog 2/3 (pSMAD2/3), platelet-derived growth factor receptor beta (PDGFRβ), galectin-7 (LGALS7), interleukin-11 (IL-11), matrix metalloproteinase-2 (MMP-2), chemokine ligand 7 (CXCL-7), soluble CD163, phosphorylated mTOR (p-mTOR), phosphorylated PDGFRβ (pPDGFRβ), prolifin (PROF1), calmodulin 2 (CALM2), calreticulin (CALR), peptidyl-prolyl cis-trans isomerase A (PPIA), or eukaryotic translation initiation factor 5A (EIF5A1).
A method of predicting or determining the efficacy of a therapeutically active agent, the method comprising:
- (a) treating a cell of a subject with interstitial lung disease with the therapeutically active agent;
- (b) measuring an expression level of a biomarker in the cell of the subject;
- wherein the biomarker is MYDGF, soluble RAGE, pSMAD2/3, PDGFRβ, pPDGFRβ, LGALS7, IL-11, MMP-2, CXCL7, sCD163, p-mTOR, PROF1, CALM2, CALR, PPIA, or EIF5A1;
- and
- (c) comparing the expression level of the biomarker to a control sample.
A method of predicting or determining the efficacy of a caveolin-1 peptide or derivative thereof, the method comprising:
- (a) treating a biological sample from a subject with fibrosis with the caveolin-1 peptide or derivative thereof;
- (b) measuring an expression level of a biomarker in the biological sample from the subject;
- wherein the biomarker is MYDGF, soluble RAGE, pSMAD2/3, PDGFRβ, pPDGFRβ, LGALS7, IL-11, MMP-2, CXCL7, sCD163, p-mTOR, PROF1, CALM2, CALR, PPIA, or IF5A1;
- and
- (c) comparing the expression level of the biomarker to a control sample.
A method of predicting or determining the efficacy of a caveolin-1 peptide or derivative thereof in a subject with fibrosis, the method comprising:
- (a) obtaining a first biological sample from the subject prior to treatment with the caveolin-1 peptide or derivative thereof;
- (b) administering the caveolin-1 peptide or derivative thereof to the subject;
- (c) obtaining a second biological sample from the subject following treatment with the caveolin-1 peptide or derivative thereof;
- (d) measuring an expression level of a biomarker in the first biological sample and the second biological sample;
- wherein the biomarker is MYDGF, soluble RAGE, pSMAD2/3, PDGFRβ, pPDGFRβ, LGALS7, IL-11, MMP-2, CXCL7, sCD163, p-mTOR, PROF1, CALM2, CALR, PPIA, or IF5A1;
- and
- (e) comparing the expression level of the biomarker in the first biological sample to the expression level of the biomarker in the second biological sample.
Dependencies are inferred from the claim text.